HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Axel Haverich Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strüber, M. Articles by Haverich, A. Search for Related Content PubMed PubMed Citation Articles by Strüber, M. Articles by Haverich, A. Related Collections Lung - transplantation

Eur J Cardiothorac Surg 2001;19:190-194
© 2001 Elsevier Science NL

Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation

^a Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl Neuberg Strasse 1, 30623 Hannover, Germany
^b Department of Pneumology, Hannover Medical School, Hannover, Germany

Received 5 July 2000; received in revised form 3 November 2000; accepted 15 November 2000.

Corresponding author. Tel.: +49-511-532-6588; fax: +49-511-532-5404
e-mail: strueber{at}thg.mh-hannover.de

	Abstract

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 
Objectives: We have previously demonstrated experimentally an amelioration of reperfusion injury of the lung after preservation using low potassium dextran (LPD) solution compared to Euro–Collins (EC) solution. Now we report on early graft function in 106 lung transplant recipients of LPD or EC preserved grafts. Methods: Initial graft function was assessed by measurement of lung compliance and oxygenation index 2 h after transplantation. Length of stay on the intensive care unit and hours of mechanical ventilation were compared. Correlation of donor oxygenation, ischemic time, type of transplant, recipient age and sex as well as initial lung compliance and oxygenation with early postoperative course were calculated. Results: Dynamic lung compliance was significantly (P<0.05) improved in the LPD group. PO₂/fiO₂ was comparable in both groups (303±122 mmHg LPD, 282±118 mmHg EC). Mechanical ventilation was used for 321±500 h in the EC group and 189±365 h in the LPD group (P=0.006). Intensive care therapy was required for 17.2±23.7 days in the EC group and 10.4±16 days in the LPD group (P=0.012). Significantly higher lung function parameters were obtained in extubated recipients of LPD preserved grafts 2 weeks after TX. Thirty day graft survival was improved in the LPD group (P=0.045). In the EC group, 30 day mortality was 14.2 and 8% in the LPD group. Conclusions: A reduction of perioperative mortality and morbidity suggests that LPD solution has superior early graft function compared to lung preservation using EC solution.

Key Words: Lung transplantation • Surfactant • Reperfusion injury • Preservation solution • Low potassium dextran solution

	1. Introduction

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 
Pulmonary allograft reperfusion injury remains a significant and common problem in clinical lung transplantation. Perioperative mortality still is in the range of 10–20%. Reperfusion injury is one of the most frequent causes of early death after lung transplantation [1]. The incidence of reperfusion injury has been reported to range from 20 to 40% in different lung transplant programs [2]. Clinical symptoms range from mild reduction of compliance to edema and failure of the graft. The requirement of extracorporeal support due to graft failure of the lung was reported in 7.4% of 215 recipients [3]. Therefore, numerous studies were conducted to elucidate the pathophysiology of reperfusion injury of the lung and to improve early graft function. It was shown that the integrity of endothelial cells and of alveolar type II cells is of importance for the initial graft function [4]. Euro–Collins (EC) solution, which is the most commonly used clinical lung preservation solution, is of intracellular ion composition (Table 1). This solution as well as other high potassium containing perfusates was shown to impair pulmonary arterial endothelial cell function [5]. Solutions with extracellular ion composition, such as low potassium dextran (LPD) solution, were found to be superior to EC with regard to preservation of endothelial function [6]. In addition, preservation of type II pneumocytes with LPD solution revealed less cytotoxicity and improved cellular metabolic activity when compared to EC solution [7]. In an experimental study using minipigs we found an amelioration of reperfusion injury of lungs preserved with LPD solution compared to EC. In addition, surfactant activity was severely impaired in the EC group, but well preserved in LPD perfused lungs [8].

	2. Patients and methods

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 
From April 1996 to October 1999 lung transplants were performed in 120 recipients at our institution. LPD solution for preservation of the lung was used in 57 grafts from April 1998 to October 1999. The remaining 63 lungs were perfused with EC solution and transplanted from April 1996 to April 1998. This group serves as a historic control group. Recipients who were on mechanical ventilation or extracorporeal support prior to transplantation were excluded from the study (six patients in the LPD group and eight patients in the EC group). Fifty-one recipients of LPD perfused grafts were included in the analysis and 55 patients with EC perfusion were included. The mean recipient age in the EC group was 42±12 years (range 16–62 years) and in the LPD group 38.9±11 years (range 19–59 years). Twenty-nine patients of the EC group were female and 26 were male. In the LPD group 21 recipients were female and 30 were male. EC perfused grafts were used for 11 single lung transplantations and for 44 cases of bilateral grafting. In the LPD group, nine single lungs were transplanted and 42 bilateral transplants were performed. The diagnoses of the recipients are shown in Fig. 1.

View larger version (39K): [in this window] [in a new window]   Fig. 1. Diagnosis of recipients of LPD or EC preserved lung transplants.

Lung transplants were performed as single lung grafting in patients with fibrosis and an absence of bronchiectasis. In all other cases bilateral sequential transplantation was carried out. All patients with a diagnosis of PPHT were electively planned for use of extracorporeal circulation (ECC) (15% EC, 10% LPD). In addition, an inability to place a double lumen tracheal tube for malformation of the trachea (10% in both groups) led to elective use of ECC. In all other cases an indication for ECC was impairment of right heart function after clamping of the right pulmonary artery or inadequate gas exchange after transplantation of the first lung in double lung procedures. ECC was required in 53% of procedures with EC perfused grafts and in 58% of procedures with LPD preserved lungs.

For assessment of initial graft function PO₂/fiO₂ was determined 2 h after the procedure. In addition, pulmonary vascular resistance was calculated after measurement of cardiac output by thermodilution methods using a Swan-Ganz catheter. Dynamic compliance was computed by the mechanical ventilator (Evita 4, Dräger, Lübeck, Germany). Patients were ventilated in a pressure controlled mode with a positive end-expiratory pressure of 10 mmHg and an inspiration/expiration time ratio of 1:1. Other indicators of postoperative graft function were time of extubation and time of transfer to a regular ward. Additional end-point parameters for this study were 30 day mortality, 30 day graft survival and spirometry parameters (FeV₁ and vital capacity (VC)) 1 and 4 weeks after transplantation for extubated patients. A long-term intensive care unit (ICU) requirement was proposed as a mechanical ventilation for more than 100 h or a length of stay in an ICU of more than 10 days. Correlations of recipient age, diagnosis, sex, donor PO₂/fiO₂, ischemic time, type of preservation solution and initial compliance after TX were calculated with postoperative compliance, PO₂/fiO₂, duration of intensive care and mechanical ventilation as well as spirometry data 1 and 4 weeks after TX and the 30 day graft survival.

2.1. Statistics and data analysis
All data are presented as the mean±SD. To compare the effects of the preservation solution the Mann–Whitney U-test was performed. Bivariate correlations were calculated using Spearman rank correlations. The SPSS statistical program for the PC was used for all calculations and statistical analysis. A P value of less than 5% was considered as statistically significant.

	3. Results

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 
Compliance of the lung 2 h after transplantation was 30±10 ml/mmHg in the EC group and 34±11 ml/mmHg in LPD preserved grafts (P=0.04). PO₂/fiO₂ was comparable at this time (303±122 mmHg for LPD and 282±120 mmHg for EC). Mechanical ventilation was required for 321±500 h in the EC group (median 57 h) and 189±365 h (P=0.006) in patients with LPD perfused grafts (median 45 h) (Fig. 2). Intensive care therapy (Fig. 3) was shorter in the LPD group (10.4±16 days) compared to EC graft recipients (17.2±23.4 days, P=0.012). Long-term ICU therapy was required in 47% of patients with EC preserved lungs. In contrast, 20% of recipients in the LPD group needed long-term ICU support (mechanical ventilation for more than 100 h or ICU stay of more than 10 days). The perioperative mortality (30 days) was higher (14.2%) in the EC group compared to recipients of LPD preserved grafts (8.0%).

View larger version (45K): [in this window] [in a new window]   Fig. 2. ICU therapy requirements in days are shown for patients with LPD and EC preserved lungs and diagnosis prior to transplantation. Data are expressed as mean values.

View larger version (48K): [in this window] [in a new window]   Fig. 3. Time of mechanical ventilation after lung transplantation shown for patients with LPD and EC preserved lungs and diagnosis prior to transplantation. Data are expressed as mean values.

View larger version (49K): [in this window] [in a new window]   Fig. 4. Spirometry data of extubated patients 2 and 4 weeks after lung transplantation. Data are expressed as mean values.

	4. Discussion

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 
This study represents a retrospective clinical analysis on the impact of a different preservation solution on the early results after lung transplantation. It shares the disadvantages of such study designs in that both groups do not match exactly in terms of patient selection and type of procedures. In addition, a general learning curve leading to an improvement of results can not be excluded by statistical methods. Recipients of EC preserved grafts were transplanted from 1996 to 1998 and served as a historic control group. LPD perfused grafts were used from 1998 to 1999.

However, there are no multicenter prospective trials on the effect of different preservation solutions in lung transplantation. This may be because the number of lung transplants is quite low and the patients are different not only in age and gender, but also in their diagnosis, which may have an influence on the postoperative course. Preservation procedures, transplantation and postoperative care may be standardized for a single center, but are of high variance at different centers.

During this study the criteria for acceptance of donor lungs, standards for procurement of the grafts, surgical procedure, anesthesia, postoperative care and immunosuppressive protocol remained unchanged, since they were developed in the earlier experience of the program from 1989 to 1996.

With the above-mentioned limitations of the study, a significant improvement of the perioperative graft with cold EC or University of Wisconsin solution function and survival was found in the LPD preserved group, leading to a reduction of the intensive care requirement which was measured by hours of mechanical ventilation and stay at the ICU. The length of mechanical ventilation shows high standard deviations in both groups. It is determined by the group of patients who need long-term ICU treatment after lung transplantation. This group was defined as requiring more than 100 h of mechanical ventilation or an ICU stay of more than 10 days. An incidence of 47% of those patients in the EC group has to be attributed in part to postoperative graft function and in part to patient selection. The waiting list of a large European lung transplant center is characterized by a high number of patients waiting for more than 2 years until a donor organ is available, while becoming a ‘borderline’ transplant candidate due to deteriorated physical status, a high incidence of prior thoracic surgery and a 10% incidence of retransplant procedures for bronchiolitis obliterans syndrome. These recipients were not excluded from the study. Since the selection criteria were unchanged for the recipients in this study, a reduction of long-term ICU requirements to 20% in the LPD group seems to indicate that LPD perfused grafts are more adequate for this patient population. A likely explanation is the amelioration of reperfusion injury LPD perfused grafts. The most common preservation method of the lung is flush perfusion. Reperfusion injury is a common complication after lung TX. In approximately 15% of cases it leads to graft failure [9], and in an even higher percentage the amelioration of reperfusion injury leads to a less severe disturbed graft function. Therefore, many experimental studies were conducted to modify both solutions in order to improve the quality of the graft and to extend the ischemic time. None of the modifications were accepted generally for clinical practice with the exception of prostacyclin for flush perfusion with EC solution. LPD solution is significantly different to EC and University of Wisconsin solution, because the ion composition is of extracellular composition. In numerous experimental studies a protective effect of LPD solution on endothelial function and type II pneumocytes was found [6,7]. Endothelial dysfunction may cause pulmonary hypertension and leukocyte sequestration. Impairment of type II cells may lead to a reduction of surfactant function. A capillary leakage due to leukocyte sequestration may further aggravate surfactant dysfunction by inactivation of surfactant due to plasma proteins [10] leaking into the alveolar space. Although this study was not designed to highlight the pathophysiology of lung reperfusion injury, it is already known that pulmonary hypertension and surfactant dysfunction [11] are features of graft dysfunction after lung transplantation [12]. Treatment strategies include the use of nitric oxide which may counteract endothelial dysfunction and surfactant replacement [13]. Therefore, it may be speculated that beneficial effects of the preservation of endothelial cells and pneumocytes are possible mechanisms for the improvement of perioperative graft function. In 1999, the lung transplant group from Munich published similar favorable clinical results with the use of LPD solution. A reduction of reperfusion injury was described in the LPD group. The higher number of single lung transplants and the use of relatively old data in the EC group weaken this study [14] but it is supportive to our findings.

In addition, an improvement in lung compliance was found after transplantation as well as higher spirometry values in the first month after the procedure in patients with LPD preserved grafts. In part this may be due to differences between the study groups. There was a higher number of women in the EC group which may have caused a bias towards transplantation of smaller lungs in this group. However, this difference was not of statistical significance (P=0.11).

An intragroup comparison of the postoperative courses revealed a high variation in terms of mechanical ventilation and intensive care requirement. Patients with emphysema seemed to have a more favorable postoperative course in both groups, although the differences were not of statistical significance. In the LPD group there were more recipients with cystic fibrosis and fibrosis and less patients with a diagnosis of primary pulmonary hypertension and emphysema. Since patients with cystic fibrosis had a comparable postoperative course to patients with fibrosis or PPHT, the differences in the diagnosis cannot explain the generally more favorable course of recipients of the LPD group. In this study it was shown that initial dynamic lung compliance is predictive of the length of stay in intensive care, mechanical ventilation as well as graft survival and spirometry values. This parameter may reflect graft quality at a very early postoperative phase. It can be speculated that improved initial graft compliance is associated with proper surfactant function. Further clinical studies have to verify this hypothesis. In addition, donor PO₂/fiO₂ which is often used for assessment of graft quality did not correlate with early graft function and should not be overestimated for this purpose.

In conclusion, this retrospective analysis of more than 100 lung transplants revealed an improvement of perioperative mortality and morbidity with the change of the preservation protocol from flush perfusion with EC to LPD solution. Clinical use of LPD solution is encouraged. A multicenter prospective randomized trial is required to verify these results. In addition, long-term results of graft function after preservation with LPD solution are pending.

	Footnotes

 
Presented at the 14th Annual Meeting of the European Association for Cardio-thoracic Surgery, Frankfurt, Germany, October 9–11, 2000.

	References

Top Abstract 1. Introduction 2. Patients and methods 3. Results 4. Discussion References

 

1. Cooper J.D., Patterson G.A., Trulock E.P., Washington University Lung Transplant Group. Results of 131 consecutive single and bilateral lung transplant recipients. J Thorac Cardiovasc Surg 1994;107:460-471.[Abstract/Free Full Text]
2. Colquhoun I.W., Kirk A.J.B., Au J., Conacher I.D., Corris P.A., Hilton C.J., Dark J.H. Single flush perfusion with modified Euro-Collins solution: experience in clinical lung preservation. J Heart Lung Transplant 1992;11:S209-S214.[Medline]
3. Glassman L.R., Keenan R.J., Fabrizio M.C., Sonett J.R., Bierman M.I., Pham S.M., Griffith B.P. Extracorporeal membrane oxygenation as an adjunct for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995;110:723-727.[Abstract/Free Full Text]
4. Novick R.J., Gehman K.E., Ali I.S., Lee J. Lung preservation: the importance of endothelial and alveolar type II cell integrity. Ann Thorac Surg 1996;62:302-314.[Abstract/Free Full Text]
5. Strüber M., Ehlers K.A., Nielsson F.N., Miller V.M., McGregor C.G.A., Haverich A. Effect of lung preservation with Euro-Collins and University of Wisconsin solution on endothelium dependent relaxations. Ann Thorac Surg 1997;63:1428-1435.[Abstract/Free Full Text]
6. Ingemansson R., Massa G., Pandita R.K., Sjöberg T., Steen S. Perfadex is superior to Euro-Collins solution regarding 24 hour preservation of vascular function. Ann Thorac Surg 1995;60:1210-1214.[Abstract/Free Full Text]
7. Maccherini M., Keshavjee S.H., Slutsky A.S., Patterson G.A., Edelson J.D. The effect of low-potassium dextran versus Euro-Collins solution for preservation of isolated type II pneumocytes. Transplantation 1991;52:621-626.[Medline]
8. Strüber M., Hohlfeld J.M., Fraund S., Kim P., Warnecke G., Haverich A. Low potassium dextran solution ameliorates reperfusion injury of the lung and protects surfactant function. J Thorac Cardiovasc Surg 2000;120:566-572.[Abstract/Free Full Text]
9. Arcasoy S.M., Kotloff R.M. Lung transplantation. N Engl J Med 1999;340:1081-1091.[Free Full Text]
10. Fuchimukai T., Fujiwara T., Takahashi A., Enhorning G. Artificial pulmonary surfactant inhibited by proteins. Appl J Physiol 1987;62:429-437.
11. Novick R.J., MacDonald J., Veldhuizen R.A., Wan F., Duplan J., Denning L., Posmayer F., Gilpin A.A., Yao L.J., Bjarneson D., Lewis J.F. Evaluation of surfactant replacement treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med 1996;154:98-104.[Abstract]
12. Hohlfeld J.M., Tiryaki E., Hamm H., Hoymann H.G., Krug N., Haverich A., Fabel H. Pulmonary surfactant activity is impaired in lung transplant recipients. Am J Respir Crit Care Med 1998;158(3):706-712.[Abstract/Free Full Text]
13. Strüber M., Brandt M., Cremer J., Harringer W., Hirt S.W., Haverich A. Therapy for lung failure using nitric oxide and surfactant replacement. Ann Thorac Surg 1996;61:1543-1545.[Abstract/Free Full Text]
14. Müller C., Fürst H., Reichenspurner H., Briegel J., Groh J., Reichart B. Lung procurement by low-potassium dextran and the effect on preservation injury. Transplantation 1999;68:1139-1143.[Medline]

This article has been cited by other articles:

				M. Wu, Q. Yang, A. P.C. Yim, M. J. Underwood, and G.-W. He Cellular electrophysiologic and mechanical evidence of superior vascular protection in pulmonary microcirculation by Perfadex compared with Celsior. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 492 - 498. [Abstract] [Full Text] [PDF]

				P. Ferraro, J. Martin, J. Dery, J. Prenovault, L. Samson, M. Coutu, L.-Q. Chen, C. Poirier, N. Noiseux, A. Duranceau, et al. Late Retrograde Perfusion of Donor Lungs Does Not Decrease the Severity of Primary Graft Dysfunction Ann. Thorac. Surg., October 1, 2008; 86(4): 1123 - 1129. [Abstract] [Full Text] [PDF]

				J. S. Ganesh, C. A. Rogers, N. R. Banner, R. S. Bonser, and Steering Group of the UK Cardiothoracic Transplant Does the method of lung preservation influence outcome after transplantation? An analysis of 681 consecutive procedures. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1313 - 1321. [Abstract] [Full Text] [PDF]

				N. Pizanis, V. Milekhin, K. Tsagakis, I. Aleksic, M. Kamler, and H. Jakob PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 42 - 47. [Abstract] [Full Text] [PDF]

				M. Struber, S. Fischer, J. Niedermeyer, G. Warnecke, B. Gohrbandt, A. Gorler, A. R. Simon, A. Haverich, and J. M. Hohlfeld Effects of exogenous surfactant instillation in clinical lung transplantation: A prospective, randomized trial J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1620 - 1625. [Abstract] [Full Text] [PDF]

				T. Oto, A. P. Griffiths, F. Rosenfeldt, B. J. Levvey, T. J. Williams, and G. I. Snell Early Outcomes Comparing Perfadex, Euro-Collins, and Papworth Solutions in Lung Transplantation Ann. Thorac. Surg., November 1, 2006; 82(5): 1842 - 1848. [Abstract] [Full Text] [PDF]

				M. Strueber, S. Fischer, J. Gottlieb, A. R. Simon, H. Goerler, B. Gohrbandt, T. Welte, and A. Haverich Long-term outcome after pulmonary retransplantation. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 407 - 412. [Abstract] [Full Text] [PDF]

				Glycine intravenous donor preconditioning is superior to glycine supplementation to low-potassium dextran flush preservation and improves graft function in a large animal lung transplantation model after 24 hours of cold ischemia. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 724 - 729.

				H. B. Bittner, M. Richter, T. Kuntze, A. Rahmel, P. Dahlberg, M. Hertz, and F. W. Mohr Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 210 - 215. [Abstract] [Full Text] [PDF]

				B. A. Whitson, D. S. Nath, A. C. Johnson, A. R. Walker, M. E. Prekker, D. M. Radosevich, C. S. Herrington, and P. S. Dahlberg Risk factors for primary graft dysfunction after lung transplantation J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 73 - 80. [Abstract] [Full Text] [PDF]

				C.A. Wranning, J. Molne, R.R. El-Akouri, G. Kurlberg, and M. Brannstrom Short-term ischaemic storage of human uterine myometrium--basic studies towards uterine transplantation Hum. Reprod., October 1, 2005; 20(10): 2736 - 2744. [Abstract] [Full Text] [PDF]

				S.-P. Sommer, B. Gohrbandt, S. Fischer, J. M. Hohlfeld, G. Warnecke, M. Avsar, and M. Struber Glutathione improves the function of porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 864 - 869. [Abstract] [Full Text] [PDF]

				S. Fischer, B. Gohrbandt, P. Struckmeier, J. Niedermeyer, A. Simon, C. Hagl, K. Kallenbach, A. Haverich, and M. Struber Lung transplantation with lungs from donors fifty years of age and older J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 919 - 925. [Abstract] [Full Text] [PDF]

				B. Gohrbandt, S. P. Sommer, S. Fischer, J. M. Hohlfeld, G. Warnecke, A. Haverich, and M. Strueber Iloprost to improve surfactant function in porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 80 - 86. [Abstract] [Full Text] [PDF]

				S. P. Sommer, G. Warnecke, J. M. Hohlfeld, B. Gohrbandt, J. Niedermeyer, T. Kofidis, A. Haverich, and M. Struber Pulmonary preservation with LPD and celsior solution in porcine lung transplantation after 24 h of cold ischemia Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 151 - 157. [Abstract] [Full Text] [PDF]

				M. de Perrot, W. Weder, G.A. Patterson, and S. Keshavjee Strategies to increase limited donor resources Eur. Respir. J., March 1, 2004; 23(3): 477 - 482. [Abstract] [Full Text] [PDF]

				I. Kutschka, S. P. Sommer, J. M. Hohlfeld, G. Warnecke, M. Morancho, S. Fischer, A. Haverich, M. Struber, and the Hannover Thoracic Transplant Program In-situ topical cooling of lung grafts: early graft function and surfactant analysis in a porcine single lung transplant model Eur. J. Cardiothorac. Surg., September 1, 2003; 24(3): 411 - 419. [Abstract] [Full Text] [PDF]

				R. F. Kelly, J. Murar, Z. Hong, D. P. Nelson, F. Hong, A. Varghese, and E. K. Weir Low potassium dextran lung preservation solution reduces reactive oxygen species production Ann. Thorac. Surg., June 1, 2003; 75(6): 1705 - 1710. [Abstract] [Full Text] [PDF]

				T. Wittwer, J. M. Albes, A. Fehrenbach, T. Pech, U. F. W. Franke, J. Richter, and T. Wahlers Experimental lung preservation with Perfadex: Effect of the NO-donor nitroglycerin on postischemic outcome J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1208 - 1216. [Abstract] [Full Text] [PDF]

				T. M. Aziz, T. M. Pillay, P. A. Corris, J. Forty, C. J. Hilton, A. Hasan, and J. H. Dark Perfadex for clinical lung procurement: is it an advance? Ann. Thorac. Surg., March 1, 2003; 75(3): 990 - 995. [Abstract] [Full Text] [PDF]

				M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]

				F. R Rega, E. J Vandezande, N. C Jannis, G. M Verleden, T. E Lerut, and D. E. Van Raemdonck The role of leukocyte depletion in ex vivo evaluation of pulmonary grafts from (non-)heart-beating donors Perfusion, January 1, 2003; 18(1_suppl): 13 - 21. [Abstract] [PDF]

				M. de Perrot and S. Keshavjee Lung preservation Ann. Thorac. Surg., August 1, 2002; 74(2): 629 - 631. [Full Text] [PDF]

				G. Warnecke, M. Struber, J. M. Hohlfeld, J. Niedermeyer, S. P. Sommer, and A. Haverich Pulmonary preservation with Bretscheider's HTK and Celsior solution in minipigs Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1073 - 1079. [Abstract] [Full Text] [PDF]

				M. Struber, J. M. Hohlfeld, T. Kofidis, G. Warnecke, J. Niedermeyer, S. P. Sommer, and A. Haverich Surfactant function in lung transplantation after 24 hours of ischemia: Advantage of retrograde flush perfusion for preservation J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 98 - 103. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Axel Haverich Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strüber, M. Articles by Haverich, A. Search for Related Content PubMed PubMed Citation Articles by Strüber, M. Articles by Haverich, A. Related Collections Lung - transplantation